2-溴-4,6-二氟苯胺氢溴酸 | 101471-20-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-溴-4,6-二氟苯胺氢溴酸
• 英文名称: 2-bromo-4,6-difluoroaniline hydrobromide
• 英文别名: 2-bromo-4,6-difluoroaniline.HBr；2-bromo-4,6-difluoroaniline;hydrobromide
• CAS: 101471-20-9
• 化学式: BrH*C₆H₄BrF₂N
• mdl: MFCD00236594
• 分子量: 288.917
• InChiKey: OYZFQVSHRSBJIJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2921420090

反应信息

• 作为反应物：
  描述：

  2-溴-4,6-二氟苯胺氢溴酸 在 sodium hypophosphite 、 氢溴酸 、 sodium nitrite 作用下， 生成 1-溴-3,5-二氟苯
  参考文献：
  名称：

  取代1-苄基咪唑-2-硫醇作为多巴胺β-羟化酶的有效和口服活性抑制剂。

  摘要：

  DOI：

  10.1021/jm00156a002
• 作为产物：
  描述：

  2,4-二氟苯胺 在 溴 作用下， 以 溶剂黄146 为溶剂， 反应 0.25h， 以91%的产率得到2-溴-4,6-二氟苯胺氢溴酸
  参考文献：
  名称：

  Multisubstrate inhibitors of dopamine .beta.-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site

  摘要：

  1-Aralkylimidazole-2-thiones have been shown to be potent multisubstrate inhibitors of dopamine beta-hydroxylase (DBH; EC 1.14.17.1). In the present study, a series of 1-benzylimidazole-2-thiones was prepared to explore the effects of substitution in the benzyl ring on the inhibition of DBH. A detailed structure-activity relationship for in vitro activity was discovered and this was shown by a modified Hansch analysis to correlate (r = 0.91) with four key structural features of the benzyl ring: the presence of a hydroxyl at the 4-position, molar refractivity at the 3-, 4-, and 5-positions, inductive effects of the substituents at the 3-, 4-, and 5-positions, and pi-electron density. The affinity (Kis) of eight substituted inhibitors for DBH was shown to correlate (r = 0.75) with the affinity (KD) of comparably substituted tyramines for the ternary DBH-oxygen-tyramine complex. This correlate is used to support the hypothesis that binding of inhibitor to DBH occurs in a fashion that mimics the binding of tyramine substrates. The most potent inhibitors were selected for study in vivo in the spontaneously hypertensive rat model of hypertension. The changes in vascular dopamine and norepinephrine levels that resulted from oral administration of the inhibitors corresponded to the observed reduction in mean arterial blood pressure. A divergence between in vitro potency and in vivo efficacy upon oral dosing was noted and is suggested to result from an in vivo metabolic conjugation of the phenolic group of inhibitor.

  DOI：

  10.1021/jm00386a008

文献信息

• Preparation of 3-halo-halobenzenes and 1-halo-3,5-dihalobenzenes
  申请人：Mallinckrodt Specialty Chemicals Company

  公开号：US05157169A1

  公开（公告）日：1992-10-20

  In a process for producing a 3-halo-halobenzene or a 1-halo-3,5-dihalobenzene, a 2-halo-4-haloaniline or 2-halo-4,6-dihaloaniline is mixed with a deaminating agent. The 2-halo-4-haloaniline or 2-halo-4,6-dihaloaniline is deaminated so as to form a corresponding 3-halo-halobenzene or 1-halo-3,5-dihalobenzene.

  在制备3-卤代卤苯或1-卤代-3,5-二卤代苯的过程中，将2-卤代-4-卤基苯胺或2-卤代-4,6-二卤基苯胺与去氨剂混合。将2-卤代-4-卤基苯胺或2-卤代-4,6-二卤基苯胺脱氨，形成相应的3-卤代卤苯或1-卤代-3,5-二卤代苯。
• PROCESS FOR PREPARING 3,5-DIFLUOROANILINE
  申请人：Basf Corporation

  公开号：EP1104399A1

  公开（公告）日：2001-06-06
• US5157169A
  申请人：——

  公开号：US5157169A

  公开（公告）日：1992-10-20
• US5977412A
  申请人：——

  公开号：US5977412A

  公开（公告）日：1999-11-02
• [EN] PREPARATION OF 3-HALO-HALOBENZENES AND 1-HALO-3,5-DIHALOBENZENES
  申请人：MALLINCKRODT SPECIALTY CHEMICALS COMPANY

  公开号：WO1993019026A1

  公开（公告）日：1993-09-30

  (EN) In a process for producing a 3-halo-halobenzene or a 1-halo-3,5-dihalobenzene, a 2-halo-4-haloaniline or 2-halo-4,6-dihaloaniline is mixed with a deaminating agent. The 2-halo-4-haloaniline or 2-halo-4,6-dihaloaniline is deaminated so as to form a corresponding 3-halo-halobenzene or 1-halo-3,5-dihalobenzene.(FR) L'invention concerne un procédé de production de 3-halo-halobenzène ou de 1-halo-3,5-dihalobenzène, qui consiste à mélanger une 2-halo-4-haloaniline ou une 2-halo-4,6-dihaloaniline avec un agent de désamination. La 2-halo-4-haloaniline ou la 2-halo-4,6-dihaloaniline est désaminée de manière à former un 3-halo-halobenzène ou un 1-halo-3,5-dihalobenzène correspondant.